Study of Erenumab (AMG 334) in Women With Hot Flashes
Status:
Completed
Trial end date:
2014-03-11
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to evaluate the frequency of moderate to severe daily
hot flashes 4 weeks after a single dose of erenumab (AMG 334) in women with hot flashes
associated with menopause.